OGIK1902

Phase 2

• Conditions: non-small cell lung cancer

• Registration Number: JPRN-jRCTs071200019
• Lead Sponsor: Harada Taishi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-06-29
• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

1)Patients with histologically or cytologically confirmed non-small cell lung cancer.
2)No prior history of chemotherapy, thoracic radiotherapy or surgical resection
3)Unresectable stage 3disease.
4)V20 is under 35%.
5)There is measurable region.
6)Age>=75
7)Eastern Cooperative Oncology Group performance status=<1
8)Leucocyte>=4000/mm3, Neutrocyte>=2000/mm3, platelets>=100000/mm3, hemoglobin>=9.0g/dl, AST and ALT=<100, bilirubin=<1.5mg/dl and serum creatinine=<1.5mg/dl. PaO2>=65torr or SpO2>=92%
9)Written informed consent.

Exclusion Criteria

1)Involvement of contralateral hilar lymph nodes.
2)Interstitial pneumonia or pulmonary fibrosis detected with chest X-ray.
3)SVC syndrome.
4)Obstructive pneumonia or active severe infection.
5)Other active invasive malignancies
6)Severe complications such as gastrointestinal bleeding, significant heart failure or uncontrolled diabetes and so on.
7)History of severe hypersensitivity.
8)Regular use of corticosteroids.
9)Mental illness
10)Pregnant woman and lactating woman
11)Active hepatitis B
12)A case considered by an investigator inadequate for the trial.

Study & Design

• Study Type: Interventional
• Study Design: Not specified